Home › Brain Tumors › Massachusetts
Brain Tumors clinical trials in Massachusetts
29 studies for Brain Tumors are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07492680Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT04899908Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05386108Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT04033497A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06253871A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07428616Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
- Brigham and Women's Hospital / Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07132190Targeted Pediatric High-Grade Glioma Therapy
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
- Brigham and Women's Hospital, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07130786B7-H3.CD28Z.CART in CNS Neoplasms
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Sep 3, 2026 · NCT07390539Study of Olutasidenib and Temozolomide in HGG
- Susan Chi, Boston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
- Massachusetts General Hospital, Boston
Recruiting
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT03286335Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Beth Israel Deaconess Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
RecruitingObservational study
All ages · All sexes · Updated Jul 22, 2026 · NCT04427384Palbociclib and Pembrolizumab In Central Nervous System Metastases
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT02896335Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- Tufts Medical Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 9, 2026 · NCT03550391Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253NTS-WBRT in Brain Metastases
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT05013892Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544NeuroPathways Intervention for Brain Tumor Patients
- Massachusetts General Hospital Cancer Center, Boston
Recruiting
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT05976490Stereotactic Magnetic Resonance Guided Radiation Therapy
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Nov 13, 2025 · NCT04115254S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Lahey Hospital and Medical Center, Burlington
- Winchester Hospital, Winchester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2025 · NCT03418961A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 11, 2025 · NCT06552260A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 1/2
Ages 18 to 89 · All sexes · Updated Aug 19, 2025 · NCT06907043ASCENT Intervention for Brain Tumor Patients
- Massachusetts General Hospital Cancer Center, Boston
Recruiting
Ages 18 and older · All sexes · Updated Jul 14, 2025 · NCT06099743The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Feb 22, 2024 · NCT06118723The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
- Massachusetts General Hospital, Boston
RecruitingObservational study
Up to age 90 · All sexes · Updated Feb 22, 2024 · NCT06273176From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.